CL2012002705A1 - Composicion farmaceutica que comprende: a) 0,1-20% de ropivacaina,bupivacaina o levobupivacaina, b) 15 a 70% en peso de un monoglicerido de acido graso de cadena larga o sus mezclas, c) 5 a 60% de un acido graso libre saturado o instaurado de cadena larga y d)menos de 30% de agua; uso para reducir el dolor. - Google Patents

Composicion farmaceutica que comprende: a) 0,1-20% de ropivacaina,bupivacaina o levobupivacaina, b) 15 a 70% en peso de un monoglicerido de acido graso de cadena larga o sus mezclas, c) 5 a 60% de un acido graso libre saturado o instaurado de cadena larga y d)menos de 30% de agua; uso para reducir el dolor.

Info

Publication number
CL2012002705A1
CL2012002705A1 CL2012002705A CL2012002705A CL2012002705A1 CL 2012002705 A1 CL2012002705 A1 CL 2012002705A1 CL 2012002705 A CL2012002705 A CL 2012002705A CL 2012002705 A CL2012002705 A CL 2012002705A CL 2012002705 A1 CL2012002705 A1 CL 2012002705A1
Authority
CL
Chile
Prior art keywords
long chain
weight
saturated
fatty acid
mixtures
Prior art date
Application number
CL2012002705A
Other languages
English (en)
Spanish (es)
Inventor
Mark Sundberg
Arne Brodin
Jonas Gustafsson
Original Assignee
Pharmanest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44278867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002705(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmanest Ab filed Critical Pharmanest Ab
Publication of CL2012002705A1 publication Critical patent/CL2012002705A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/10—Medicinal preparations other than biologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/15—Laboratory, medical or dentistry appliances, e.g. catheters or sharps
    • A61L2103/20—Containers, e.g. vials or flasks

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012002705A 2010-04-01 2012-09-27 Composicion farmaceutica que comprende: a) 0,1-20% de ropivacaina,bupivacaina o levobupivacaina, b) 15 a 70% en peso de un monoglicerido de acido graso de cadena larga o sus mezclas, c) 5 a 60% de un acido graso libre saturado o instaurado de cadena larga y d)menos de 30% de agua; uso para reducir el dolor. CL2012002705A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1050322 2010-04-01
US32542510P 2010-04-19 2010-04-19

Publications (1)

Publication Number Publication Date
CL2012002705A1 true CL2012002705A1 (es) 2013-02-01

Family

ID=44278867

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002705A CL2012002705A1 (es) 2010-04-01 2012-09-27 Composicion farmaceutica que comprende: a) 0,1-20% de ropivacaina,bupivacaina o levobupivacaina, b) 15 a 70% en peso de un monoglicerido de acido graso de cadena larga o sus mezclas, c) 5 a 60% de un acido graso libre saturado o instaurado de cadena larga y d)menos de 30% de agua; uso para reducir el dolor.

Country Status (17)

Country Link
US (1) US20130079371A1 (enExample)
EP (1) EP2552409A1 (enExample)
JP (1) JP2013523694A (enExample)
KR (1) KR20130080435A (enExample)
CN (1) CN102869344A (enExample)
AU (1) AU2011234415C1 (enExample)
BR (1) BR112012024885A2 (enExample)
CA (1) CA2794280A1 (enExample)
CL (1) CL2012002705A1 (enExample)
EA (1) EA201290790A1 (enExample)
IL (1) IL222225A0 (enExample)
MX (1) MX2012011261A (enExample)
NZ (1) NZ602540A (enExample)
PH (1) PH12012501887A1 (enExample)
SG (1) SG184072A1 (enExample)
WO (1) WO2011121082A1 (enExample)
ZA (1) ZA201206989B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US9642912B2 (en) 2006-03-06 2017-05-09 Crescita Therapeutics Inc. Topical formulations for treating skin conditions
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
KR101768843B1 (ko) * 2013-02-28 2017-08-17 미라 파마 코포레이션 주사가능 장기-작용 국소 마취제 반고체 제형 및 이의 조성물
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
GB201317718D0 (en) 2013-10-07 2013-11-20 Buzzz Pharmaceuticals Ltd Novel formulation
WO2016152186A1 (ja) 2015-03-25 2016-09-29 テルモ株式会社 ゲル状局所麻酔剤およびそれを用いたゲル状局所麻酔製剤
AU2016352007B2 (en) 2015-11-12 2022-03-17 Terumo Kabushiki Kaisha Sustained-release topically administered agent
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
CA3061480A1 (en) * 2017-05-08 2018-11-15 Alivio Therapeutics, Inc. Formulation of nanostructured gels for increased agent loading and adhesion
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
JP7046396B2 (ja) 2017-12-06 2022-04-04 湖州惠中濟世生物科技有限公司 注射可能な長時間作用性局所麻酔薬半固形製剤
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
CN113825495A (zh) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物
JP2024505227A (ja) * 2021-01-29 2024-02-05 インシツ バイオロジクス、インク． 疼痛の持続的治療のための組成物および方法
CN118697692B (zh) * 2024-06-27 2024-11-26 山东中医药大学附属医院 一种防苦麻醉胶浆剂、方法及应用
CN119587525B (zh) * 2024-11-07 2025-09-05 海南三帝制药有限公司 一种二甲卡因复合制剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
AU685262B2 (en) * 1994-03-30 1998-01-15 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE9601421D0 (sv) 1996-04-12 1996-04-12 Astra Ab New composition
JP2001503035A (ja) * 1996-10-14 2001-03-06 興和株式会社 外用局所麻酔剤
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
US20050084508A1 (en) 2003-07-22 2005-04-21 Vancaillie Thierry G. Topical anesthesia formulation for bodily cavities
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
JP4931369B2 (ja) 2005-05-31 2012-05-16 ポーラ化成工業株式会社 リポソームおよびそれを含む処置用の組成物
CN101374554A (zh) * 2005-09-27 2009-02-25 埃弗拉特生物聚合物有限公司 胶凝疏水性可注射聚合物组合物
GB0524958D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070269386A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
JP5181320B2 (ja) * 2006-10-18 2013-04-10 ニチバン株式会社 皮膚刺激の少ない経皮吸収型製剤
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
US20090247494A1 (en) 2008-04-01 2009-10-01 Phillip Mark Kofsky Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders

Also Published As

Publication number Publication date
AU2011234415C1 (en) 2014-07-10
CA2794280A1 (en) 2011-10-06
BR112012024885A2 (pt) 2016-06-21
PH12012501887A1 (en) 2012-12-17
MX2012011261A (es) 2012-12-05
IL222225A0 (en) 2012-12-31
JP2013523694A (ja) 2013-06-17
US20130079371A1 (en) 2013-03-28
EA201290790A1 (ru) 2013-04-30
EP2552409A1 (en) 2013-02-06
ZA201206989B (en) 2014-04-30
SG184072A1 (en) 2012-10-30
NZ602540A (en) 2014-05-30
WO2011121082A1 (en) 2011-10-06
KR20130080435A (ko) 2013-07-12
AU2011234415B2 (en) 2014-04-10
AU2011234415A1 (en) 2012-10-18
CN102869344A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
MX338324B (es) Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante.
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
BR112014029766A2 (pt) composições contendo álcoois graxos, tensoativos catiônicos e n-acil-n-metilglucaminas
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
BR112012013049A2 (pt) potencializador do efeito antitumor.
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
UA113656C2 (xx) Гербіцидна композиція, яка має поліпшену гербіцидну активність
NZ593186A (en) Fatty acids derived from hydrolysing triglycerides for inducing defecation
UA101407C2 (ru) Стабильная комбинированная фармацевтическая композиция амлодипина и бисопролола фумарат
MX2013008900A (es) Mezcla humectante mejorada.
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
UA108200C2 (uk) Лікарські форми та способи застосування ектопаразитоцидів
BR112014016308A2 (pt) composições de cuidados pessoais com pectinas acidificadas
BRPI0814115B8 (pt) composição farmacêutica compreendendo o composto 11-deóxi-prostaglandina e método para estabilizar o composto
BR112012026640A2 (pt) composição, método de amaciar um tecido e aumentar a liberação de fragância, e, uso de uma composição
EA201390460A1 (ru) Ароматизированные композиции мыла
BR112013026564A2 (pt) uso de uma combinação
UA105266C2 (ru) Композиция и способ борьбы с заболеваниями растений
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
BR112012024345A2 (pt) ésteres do tipo de piretrinoides como pesticidas
NI201500087A (es) Formulación farmacéutica de n-[5-[2-(3-,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r, 5s)-3, 5 - dimetl piperazin - 1 il] benzamida
BR112012024557A2 (pt) composto de éster e seu uso
AR080191A1 (es) Compuestos de ester y su uso en el control de plagas
BR112014014872A2 (pt) produtos de goma de mascar que contêm éster isopropílico de ácido [(2-isopropil-5-metil-ciclo-hexanocarbonil)-amino] acético